RT..ACT Secures Patent to Generate Embryonic Stem Cells Without Embryo Destruction
IP Coverage for Proprietary Single-Blastomere Technology Could Facilitate
Licensing Deals and Partnerships
MARLBOROUGH, Mass., Feb. 23, 2011 /PRNewswire via COMTEX/ -- Advanced Cell
Technology, Inc. ("ACT"; OTC Bulletin Board: ACTC), a leader in the field of
regenerative medicine, announced today that it has been issued a patent on its
"single-blastomere" technique. Patent Number 7,893,315 broadly covers ACT's
proprietary single-blastomere technology that provides a non-destructive
alternative for deriving human embryonic stem cell (hESC) lines.
"Of the more than 150 patents and patent applications related to stem cell
therapy and regenerative medicine that ACT owns or licenses, this patent on our
single-blastomere technology is one of the most significant," stated Gary Rabin,
ACT's interim chairman and CEO. "It will help us accelerate our progress on a
number of fronts, including deriving embryonic stem cells which meet the
regulatory standards of the European Medicines Agency and the US Food and Drug
Administration, using the single-blastomere technology. We are currently
developing a collaboration for creating banks of these cells using our
proprietary technique with the United Kingdom's Roslin Cells. This is an example
of the type of potentially revenue-generating future partnership that we think
this IP (intellectual property) protection could help facilitate."
The single-blastomere technology uses a one-cell biopsy approach similar to
pre-implantation genetic diagnosis (PGD), which is widely used in the in vitro
fertilization (IVF) process and does not interfere with the embryo's
developmental potential. The stem cells generated using this approach are
healthy, completely normal, and differentiate into all the cell types of the
human body, including insulin-producing cells, blood cells, beating heart cells,
cartilage, and other cell types of therapeutic importance. The safety record for
one-cell biopsy as part of PGD now has a 15-year track record, and is carried out
routinely as part of IVF processes around the world. ACT's "embryo-safe"
technique has been published in been peer-reviewed journals such as Nature and
Cell Stem Cell.
Robert Lanza, M.D., chief scientific officer of ACT, said, "This patent issuance
represents recognition of the innovation underlying our single-blastomere
technology. In the US alone, over 100 people die every hour from diseases that
could potentially benefit from this 'embryo-safe' technique. Single cells are
removed from the embryos, which remain healthy and continue to develop normally
at rates consistent with whole (non-biopsied) embryos. Furthermore, this IP
protection follows on the issuance of a broad patent relating to ACT's production
and therapeutic use of Retinal Pigment Epithelial (RPE) cells in 2010. We are
eagerly anticipating the start of the two Phase 1/2 clinical trials in the first
half of this year. Our RPE program uses hESCs derived from a single blastomere,
and as such, this source of embryonic stem cells has been subjected to extensive
regulatory scrutiny in order to demonstrate their safety and suitability to be
used in human patients on a trial basis."
ACT has been issued clearance from the FDA to proceed with two Phase 1/2 clinical
trials in the U.S. for its RPE program, including a Phase 1/2 trial in patients
with dry age-related macular degeneration.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results,
future growth in research and development programs, potential applications of our
technology, opportunities for the company and any other statements about the
future expectations, beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are not statements
of historical fact (including statements containing the words "will," "believes,"
"plans," "anticipates," "expects," "estimates," and similar expressions) should
also be considered to be forward-looking statements. There are a number of
important factors that could cause actual results or events to differ materially
from those indicated by such forward-looking statements, including: limited
operating history, need for future capital, risks inherent in the development and
commercialization of potential products, protection of our intellectual property,
and economic conditions generally. Additional information on potential factors
that could affect our results and other risks and uncertainties are detailed from
time to time in the company's periodic reports, including the report on Form 10-K
for the year ended December 31, 2009. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company's management at the time they
are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the beliefs,
opinions, and expectations of the company's management at the time they are made,
and the company does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other circumstances
should change. There can be no assurance that the Company's clinical trials will
be successful.
Contact:
Investors:
CEOcast, Inc., James Young, 212-732-4300
Press:
ACT Corporate Communications, Bill Douglass, 646-450-3615
or:
Russo Partners, Martina Schwarzkopf, Ph.D., 212-845-4292 |
